Health Effects of Sustainable Future Proteins

NCT ID: NCT03744221

Last Updated: 2019-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-05

Study Completion Date

2018-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the current study the investigators aim to assess the nutritional quality and bio-functional activity of two alternative protein sources bovine plasma and corn and from the benchmark protein whey. The study is a double blind, randomised, cross-over, short-term trial in which 36 healthy study subjects will receive three protein interventions of 1 week with a washout period of 1 week between interventions. Study subjects will visit the research facility before and after the intervention period on two separate occasions to measure gut permeability via a multi-sugar test and to collect fasting blood samples and blood pressure outcomes. Faecal and saliva samples before and after each intervention will be collected. A subgroup of 12 study participants will also be subjected to a postprandial digestibility test on the first day of the interventions. The main study parameter is to assess the protein digestion kinetics and protection of the epithelial barrier. Secondary study parameters include other markers of gastrointestinal health, metabolic health, vascular health and satiating properties.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the current study the investigators aim to assess the nutritional quality and bio-functional activity of two alternative protein sources bovine plasma and corn and from the benchmark protein whey. The objective is to assess the degree of digestibility and protection of the epithelial barrier of two alternative protein concentrates from corn and bovine plasma and of the commonly consumed benchmark protein whey. These outcomes will also be used to evaluate how predictive the in vitro-measurements have been for the obtained in vivo-effects. Secondary objectives are to assess the impact on other markers of gastrointestinal health, metabolic health, vascular health and satiating properties. Study design: The study is a double blind, randomised, cross-over, short-term trial in which 36 study subject will participate. Study subjects will receive three protein interventions of 1 week with a washout period of 1 week between interventions. Study subjects will visit the research facility before and after the intervention period on two separate occasions to measure gut permeability via a multi-sugar/acetylsalicylic acid test and to collect fasting blood samples and blood pressure outcomes. Faecal and saliva samples before and after each intervention will be collected. All measurements will be conducted after an overnight fast and a standardised evening meal prior to the study days. A subgroup of 12 study participants will also be subjected to a postprandial digestibility test on the first day of the interventions.

Study population: healthy study subjects, between 35-70y, BMI 18 - 30kg/m2, both males and females.

Intervention (if applicable): Three intervention arms of one week; a bovine plasma protein intervention, a corn protein intervention and a whey protein comparator intervention. Study subjects will receive 40 grams of protein per day during the intervention in two 20 g doses.

Main study parameters/endpoints: The main study parameter is to assess the protein digestion kinetics and protection of the epithelial barrier. Secondary study parameters include other markers of gastrointestinal health, metabolic health, vascular health and satiating properties.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intestinal Barrier Function Protein Digestion Kinetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

double blind, randomised, cross-over, short-term trial in which 36 study subject will participate. Study subjects will receive three protein interventions of 1 week with a washout period of 1 week between interventions. 12 subjects will also receive an acute postprandial digestibility test at the start of the intervention.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Proteins will be packed in non-transparent sealed sachets/jars and labeled with 'protein A/B/C'. Proteins will be flavored to mask taste

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Corn protein

Corn protein powder

Group Type EXPERIMENTAL

Corn protein powder

Intervention Type DIETARY_SUPPLEMENT

40g/d ( 2 times 20 grams per day for a period of 1 week)

Bovine plasma protein

Bovine plasma protein powder

Group Type EXPERIMENTAL

Bovine plasma protein powder

Intervention Type DIETARY_SUPPLEMENT

40g/d ( 2 times 20 grams per day for a period of 1 week)

control benchmark protein Whey

Whey protein powder

Group Type ACTIVE_COMPARATOR

Whey protein powder

Intervention Type DIETARY_SUPPLEMENT

40g/d ( 2 times 20 grams per day for a period of 1 week)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Corn protein powder

40g/d ( 2 times 20 grams per day for a period of 1 week)

Intervention Type DIETARY_SUPPLEMENT

Bovine plasma protein powder

40g/d ( 2 times 20 grams per day for a period of 1 week)

Intervention Type DIETARY_SUPPLEMENT

Whey protein powder

40g/d ( 2 times 20 grams per day for a period of 1 week)

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sustainable protein source 1 sustainable protein source 2 control protein source

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects
* Age between 35-70 y
* BMI between 18 - 30 kg/m2

Exclusion Criteria

* Intake of medications known to change the inflammatory status (including proton pump inhibitors, anti-inflammatory medication (including NSAIDs)
* Having a history of medical or surgical events that may significantly affect the study outcome
* Kidney dysfunction (self-reported)
* Gastrointestinal disorders, constipation (defecation \<3 times a week) or history of gastrointestinal surgery
* Allergies for our intervention products
* Recent use of antibiotics (\<1 month prior to day 01 of the study)
* Not having a general practitioner
* Mental status that is incompatible with the proper conduct of the study
* Pregnancy or lactating
* Reported weight loss or weight gain of \> 5 kg in the month prior to pre-study screening
* Reported slimming, medically prescribed, other (extreme) diet, or use of protein concentrates
* Not willing to give up blood donation during the study
* Current smokers
* Alcohol intake \> 3 glasses per day
* Hard-drug abuse
* Participation in other clinical trials in the past month
* Being an employee or student of the department Consumer Science \& Health group of Wageningen Food \& Biobased Research
Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wageningen University and Research

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Diederik Esser

project leader clinical trials

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Diederik Esser, Dr

Role: PRINCIPAL_INVESTIGATOR

Wageningen research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stichting Wageningen Research

Wageningen, Gelderland, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL65835.081.18

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Milk and Plant Protein Digestion
NCT06272331 COMPLETED NA
Cater With Care Effect Study
NCT02213393 COMPLETED NA